LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

Historical Holders from Q2 2015 to Q3 2025

Symbol
LXRX on Nasdaq
Type / Class
Equity / COMMON STOCK
Shares outstanding
363M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
255M
Holdings value
$344M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
121
Number of buys
44
Number of sells
-58
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 10.5% +9% $26.7M $2.52M 38.1M +10.4% FMR LLC 30 Jun 2025

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 255M $344M -$1.11M $1.35 121
2025 Q2 256M $243M -$6.85M $0.95 121
2025 Q1 266M $122M -$18.1M $0.46 124
2024 Q4 298M $220M -$8.08M $0.74 124
2024 Q3 289M $453M -$48.6M $1.57 134
2024 Q2 278M $468M +$176M $1.68 121
2024 Q1 172M $412M -$25M $2.40 114
2023 Q4 183M $280M -$6.76M $1.53 103
2023 Q3 189M $206M -$5.68M $1.09 109
2023 Q2 191M $438M +$105M $2.29 121
2023 Q1 146M $354M -$3M $2.43 102
2022 Q4 147M $281M -$3.98M $1.91 100
2022 Q3 149M $357M +$72.6M $2.40 98
2022 Q2 119M $221M -$2.43M $1.86 82
2022 Q1 120M $251M -$5.57M $2.09 100
2021 Q4 122M $479M -$1.47M $3.94 108
2021 Q3 121M $583M +$17.3M $4.81 96
2021 Q2 118M $540M +$2.12M $4.59 105
2021 Q1 121M $712M +$117K $5.87 103
2020 Q4 122M $417M +$65.7M $3.42 100
2020 Q3 104M $150M -$5.09M $1.44 83
2020 Q2 107M $214M +$4.8M $1.99 99
2020 Q1 105M $204M -$17.2M $1.95 107
2019 Q4 107M $445M +$20.4M $4.15 110
2019 Q3 102M $308M -$30M $3.01 95
2019 Q2 105M $662M +$7.04M $6.29 105
2019 Q1 104M $580M -$6.64M $5.56 112
2018 Q4 105M $700M -$17.1M $6.64 117
2018 Q3 107M $1.15B -$30M $10.67 114
2018 Q2 104M $1.25B -$372K $12.00 114
2018 Q1 110M $940M -$14.1M $8.57 118
2017 Q4 111M $1.1B -$44.2M $9.88 123
2017 Q3 110M $1.36B -$5.7M $12.29 130
2017 Q2 111M $1.82B +$18.2M $16.45 129
2017 Q1 110M $1.58B +$120M $14.34 130
2016 Q4 106M $1.47B -$2.53M $13.83 140
2016 Q3 106M $1.92B +$249K $18.07 138
2016 Q2 111M $1.59B +$1.09M $14.35 134
2016 Q1 111M $1.32B +$14M $11.95 126
2015 Q4 110M $1.46B +$55M $13.31 116
2015 Q3 106M $1.14B +$98.1M $10.74 99
2015 Q2 96.8M $779M +$779M $8.05 86